SEC Comment Letter for Bionano Genomics, Inc. (BNGO) (CIK 0001411690) (BNGO) — Mar 17, 2020
Bionano Genomics, Inc. (BNGO) (CIK 0001411690)
Date: March 17, 2020 · CIK: 0001411690 · Accession: 0000000000-20-002367
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-237074
Letter
March 16, 2020 R. Erik Holmlin, Ph.D. President and Chief Executive Officer Bionano Genomics, Inc. 9540 Towne Centre Drive, Suite 100 San Diego, California 92121 Re:Bionano Genomics, Inc. Registration Statement on Form S-1 Filed March 11, 2020 File No. 333-237074 Dear Dr. Holmlin: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at 202-551-2544 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: James Pennington, Esq.
Show Raw Text
March 16, 2020
R. Erik Holmlin, Ph.D.
President and Chief Executive Officer
Bionano Genomics, Inc.
9540 Towne Centre Drive, Suite 100
San Diego, California 92121
Re:Bionano Genomics, Inc.
Registration Statement on Form S-1
Filed March 11, 2020
File No. 333-237074
Dear Dr. Holmlin:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jeffrey Gabor at 202-551-2544 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: James Pennington, Esq.